Common Contracts
5 similar Transaction Bonus Agreement contracts by Biosante Pharmaceuticals Inc
EX-10.68 20 a2211561zex-10_68.htm EX-10.68 ANIP ACQUISITION COMPANY TRANSACTION BONUS AGREEMENTTransaction Bonus Agreement • May 5th, 2020 • Delaware
THIS TRANSACTION BONUS AGREEMENT (“Agreement”) is entered into this 22nd day of September, 2012 (the “Effective Date”), by and between ANIP Acquisition Company (the “Company”) and Robert Jamnick (the “Executive”).
ANIP ACQUISITION COMPANY TRANSACTION BONUS AGREEMENTTransaction Bonus Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS TRANSACTION BONUS AGREEMENT (“Agreement”) is entered into this 22nd day of September, 2012 (the “Effective Date”), by and between ANIP Acquisition Company (the “Company”) and Arthur Przybyl (the “Executive”).
ANIP ACQUISITION COMPANY TRANSACTION BONUS AGREEMENTTransaction Bonus Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS TRANSACTION BONUS AGREEMENT (“Agreement”) is entered into this 22nd day of September, 2012 (the “Effective Date”), by and between ANIP Acquisition Company (the “Company”) and Robert Jamnick (the “Executive”).
ANIP ACQUISITION COMPANY TRANSACTION BONUS AGREEMENTTransaction Bonus Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS TRANSACTION BONUS AGREEMENT (“Agreement”) is entered into this 22nd day of September, 2012 (the “Effective Date”), by and between ANIP Acquisition Company (the “Company”) and Charlotte Arnold (the “Executive”).
ANIP ACQUISITION COMPANY TRANSACTION BONUS AGREEMENTTransaction Bonus Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS TRANSACTION BONUS AGREEMENT (“Agreement”) is entered into this 22nd day of September, 2012 (the “Effective Date”), by and between ANIP Acquisition Company (the “Company”) and James Marken (the “Executive”).
